Innovation Pharmaceuticals Inc (IPIX)

[CallMeCrazy]

NIAID Continues Financing Brilacidin Antiviral Testing and Research

Leo's strategy, IMO, is to create revenue streams from lesser Brilacidin indications (UP/UPS, B-OM, etc), while saving the multi-billion dollar indications, like UC/CD and B-AV for IPIX to conduct clinical trials on.

NEW YORK, April 15, 2022 /PRNewswire/ -- The global gastrointestinal diseases therapeutics market size is expected to increase by USD 22.82 billion between 2019 and 2024, and the growth momentum is expected to accelerate at a CAGR of 9% during the forecast period.

https://www.prnewswire.com/news-releases/gastrointestinal-diseases-therapeutics-market-to-record-usd-22-82-bn-growth--evolving-opportunities-with-abbott-laboratories-and-abbvie-inc--technavio-301525818.html

Aug. 10, 2022 (GLOBE NEWSWIRE) -- The global antiviral drugs market is expected to clock US$ 66.79 billion by 2030 owing to presence of a well-established supply chain, rising interest in supporting the development of innovative antiviral medications and increased public awareness.

https://www.globenewswire.com/news-release/2022/08/10/2495491/0/en/Antiviral-Drugs-Market-to-Hit-US-66-79-billion-by-2030-With-3-5-of-CAGR-Growth-Plus-Reports.html

Consider: (1) The global antiviral drug market is Brilacidin's most lucrative ($66.79B) addressable market. (2) The U.S. Government, via NIAID, has spent and continues to spend money testing and researching Brilacidin against various families of viruses in order to determine the scope of Brilacidin's antiviral attribute. (3) Determining the antiviral scope of Brilacidin has and will cost millions and, without NIAID, Brilacidin's antiviral attributes would have remained largely unknown, due to IPIX's inability to finance reseach in this most lucrative "B" area.

IMO, Leo's plan is for IPIX to self-finance the clinical trials in the more lucrative areas with anticipated incoming revenue streams from partnerships on lesser "B" indications, possibly using the "small ball" revenue streams to finance UC/CD and using NIAID to lead the development of Brilacidin as an antiviral, consistent with their priorities. NIAID's willingness to potentially take a B-AV to a phase 2A will make it a lot easier to negotiate with a potential partner for a phase 3 and more.

Brilacidin is advancing on multiple fronts.

I don't understand the "ho-hum" attitude about the fact that NIAID is leading IPIX's antiviral development of Brilacidin: THE LARGEST ADRESSABLE MARKET FOR BRILACIDIN. What many can't see is that Leo is developing the pipeline in a way that best positions him to extract the highest value from partnership deals on Bs two most lucrative indications, UC/CD and antiviral.

Short-termers and the short sighted will probably never see any of this, but as a long-termer...I love what I'm seeing. Understanding Leo's strategic goal is everything.

NIAID Continues To Finance Brilacidin Testing and Research